Neoleukin Therapeutics Statistics
Share Statistics
Neoleukin Therapeutics has 2.35M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 2.35M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,000 |
| FTD / Avg. Volume | 18.12% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -2.01 and the forward
PE ratio is null.
Neoleukin Therapeutics's PEG ratio is
0.43.
| PE Ratio | -2.01 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 1.19 |
| P/FCF Ratio | -2.41 |
| PEG Ratio | 0.43 |
Financial Ratio HistoryEnterprise Valuation
Neoleukin Therapeutics has an Enterprise Value (EV) of 86.61M.
| EV / Sales | 0 |
| EV / EBITDA | -1.53 |
| EV / EBIT | -1.9 |
| EV / FCF | -1.85 |
Financial Position
The company has a current ratio of 8.96,
with a Debt / Equity ratio of 0.13.
| Current Ratio | 8.96 |
| Quick Ratio | 8.96 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | -0.21 |
| Debt / FCF | -0.26 |
| Interest Coverage | -37.36 |
Financial Efficiency
Return on Equity is -59.38% and Return on Invested Capital is -54.06%.
| Return on Equity | -59.38% |
| Return on Assets | -48.31% |
| Return on Invested Capital | -54.06% |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-8,002,428.57 |
| Employee Count | 7 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.54M |
| Effective Tax Rate | 2.68% |
Stock Price Statistics
The stock price has increased by 0% in the
last 52 weeks. The beta is 1.1, so Neoleukin Therapeutics's
price volatility has been higher than the market average.
| Beta | 1.1 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 3.46 |
| 200-Day Moving Average | 3.73 |
| Relative Strength Index (RSI) | 51.69 |
| Average Volume (20 Days) | 5,520 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -59.1M |
| Net Income | -56.02M |
| EBITDA | -56.48M |
| EBIT | -55.98M |
| Earnings Per Share (EPS) | -1.01 |
Full Income StatementBalance Sheet
The company has 37.89M in cash and 12.07M in
debt, giving a net cash position of 25.82M.
| Cash & Cash Equivalents | 37.89M |
| Total Debt | 12.07M |
| Net Cash | 25.82M |
| Retained Earnings | -451.06M |
| Total Assets | 89.59M |
| Working Capital | 74.68M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -45.61M
and capital expenditures -1.11M, giving a free cash flow of -46.72M.
| Operating Cash Flow | -45.61M |
| Capital Expenditures | -1.11M |
| Free Cash Flow | -46.72M |
| FCF Per Share | -4.23 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
